<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556255</url>
  </required_header>
  <id_info>
    <org_study_id>EX-PAD-01</org_study_id>
    <nct_id>NCT02556255</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of Eximo's B-Laser™ Atherectomy Device for PAD Treatment</brief_title>
  <official_title>Safety and Effectiveness Evaluation of Eximo's B-Laser™ Atherectomy Device, in Subjects Affected With PAD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eximo Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eximo Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety and efficacy of the use of the Eximo's B-Laser™
      catheter in subjects affected with Peripheral Artery Disease (PAD) in lower extremity
      arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, multi-center, international, open-label, non-randomized
      clinical study.

      All enrolled subjects will undergo atherectomy procedure, during which the B-Laser™ catheter
      will be used to perform atherectomy in target lesion, followed by any other adjunctive
      therapy (balloon and/or stent etc.). The procedure will be done according to standard
      hospital procedure for atherectomy. The steps of the operation before and after the operating
      of the B-Laser™ device are routinely used practice and will be done according to local
      practice at each hospital. For the post-atherectomy stage, as an adjunctive therapy in the
      procedure, any approved device may be used (balloon and/or stent etc.).

      Subjects will then be followed for 12 months after the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With 30 Day Freedom From Major Adverse Events</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Need for emergency surgical revascularization of the target limb
Unplanned target limb amputation above the ankle
Clinically driven Target Lesion Revascularization (TLR)
Cardiovascular related deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (1)</measure>
    <time_frame>Perioperative (until discharge), an average of 6 days</time_frame>
    <description>(*NOTE: Device- or procedure-related AE refers only to the ATHERECTOMY PROCEDURE (with B-Laser™) and not the entire index procedure.)
Clinically Significant Perforations requiring intervention
Clinically Significant Dissections requiring intervention
Clinically Significant Embolus requiring intervention
Clinically Pseudo-aneurysm requiring intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Lesions With Technical Success Rate: the Ability of the B-Laser™ Catheter to Cross the Target Lesion Stenosis Over the Wire.</measure>
    <time_frame>Intraoperative (during the index procedure, after B-Laser™ catheter crossing, before adjunctive therapy)</time_frame>
    <description>The technical success will be evaluated visually by the performing physician during procedure by fluoroscopy. It is evaluated per lesion and not per subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (2)</measure>
    <time_frame>Perioperative (until discharge), an average of 6 days</time_frame>
    <description>(*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.)
Emboli, defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator
Flow limiting dissection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 30 Day Freedom From Device/Procedure* Related Adverse Events</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>(*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.)
Clinically Significant Dissections requiring intervention
Clinically Significant Embolus requiring intervention
Clinically Pseudo-aneurysm requiring intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lesions With Post-intervention Residual Diameter Stenosis of &lt;30% With Adjunctive Therapy Assessed by Fluoroscopic Angiography in Cases Where Adjunctive Therapy is Medically Applicable</measure>
    <time_frame>Intraoperative (at the end of the index procedure, after the last adjunctive therapy, e.g. last balloon or last stent)</time_frame>
    <description>The ability of the B-Laser™ catheter to achieve a post-intervention residual diameter stenosis of &lt;30% with adjunctive therapy assessed by fluoroscopic angiography in cases where adjunctive therapy is medically applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle-Brachial Index (ABI) Post B-Laser™ Device Procedure Compared to Baseline</measure>
    <time_frame>baseline and 30 days, 6 months and 12 months post procedure</time_frame>
    <description>Change in Ankle-Brachial Index (ABI) post B-Laser™ device procedure compared to baseline.
ABI is calculated as the ratio of the ankle blood pressure to the arm blood pressure. The normal value ranges between 0.9 to 1.3.
The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher ABI score at the later time point represents an improvement through time and vice versa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline</measure>
    <time_frame>baseline and 30 days, 6 months and 12 months post procedure</time_frame>
    <description>Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline.
Rutherford Classification has seven stages, from Stage 0 to Stage 6, when the lower value indicate a better outcome: 0= Asymptomatic; 1= Mild claudication; 2= Moderate claudication; 3= Severe claudication; 4= Rest pain; 5= Ischemic ulceration not exceeding ulcer of the digits of the foot; 6= Severe ischemic ulcers or frank gangrene.
The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent decrease while negative results represent increases, so lower Rutherford score at the later time point represents an improvement through time and vice versa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline</measure>
    <time_frame>baseline and 30 days, 6 months and 12 months post procedure</time_frame>
    <description>Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline. WIQ score ranges from 0-100 with higher score indicating a better walking outcomes.
The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher WIQ score at the later time point represents an improvement through time and vice versa.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>B-Laser™ Atherectomy Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD), that the atherectomy part of the PTA will include an experimental atherectomy catheter, B-Laser™.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>B-Laser™ Atherectomy Catheter</intervention_name>
    <description>Laser atherectomy catheter based on 355 nm</description>
    <arm_group_label>B-Laser™ Atherectomy Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is ≥ 18 years old.

          2. Subject is a candidate for endovascular intervention for peripheral artery disease in
             the lower extremities.

          3. Documented symptomatic atherosclerotic peripheral artery disease Rutherford
             Classification 2-4.

          4. Subject has infrainguinal target lesion(s) with any type of stenosis (naïve or
             recurrent) estimated to be ≥70% based on CT angiogram or other imaging modality.

          5. At least one patent tibial run-off vessel at baseline.

          6. Subject is capable and willing to comply with the scheduled follow up.

          7. Subject is able and willing to sign a written informed consent form (ICF).

        Intraoperative inclusion criteria (by fluoroscopy angiogram):

          1. Reference vessel lumen diameter proximal to target lesion is ≥150% of the outer
             diameter of the B-Laser™ to be used.

          2. Target lesion has been crossed with a guidewire within the true lumen.

          3. Target lesion has a stenosis estimated to be ≥70%.

        Exclusion Criteria:

          1. Target lesion is in a vessel graft or synthetic graft.

          2. Target lesion length &gt;25 cm.

          3. Endovascular or surgical procedure performed less than or equal to 30 days prior to
             the index procedure OR Planned endovascular or surgical procedure 30 days after the
             index procedure.

          4. Intent to use other atherectomy device in the same procedure.

          5. Flow limiting dissection proximal to, distal to or in the target lesion.

          6. Evidence or history of intracranial or gastrointestinal bleeding, intracranial
             aneurysm, myocardial infarction or stroke within the past 2 months.

          7. Evidence or history of aneurysm in the target vessel within the past 2 months.

          8. History of bleeding diathesis, coagulopathy or inability to accept blood transfusions.

          9. History of heparin-induced thrombocytopenia (HIT).

         10. Significant acute or chronic kidney disease with a creatinine level &gt;2.5 mg/dl, and/or
             requiring dialysis.

         11. Any thrombolytic therapy within 2 weeks of the index procedure.

         12. History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ
             within the past 14 days.

         13. Known allergy to contrast agents or medications used to perform endovascular
             intervention that cannot be adequately pre-treated.

         14. Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is
             contraindicated.

         15. Serious illness that may affect subject compliance to protocol and at a minimum the
             30-day follow-up.

         16. Participating in other clinical study that involves any kind of intervention,
             including pharmaceutical.

         17. Issue that in the judgment of the investigator, may affect the results of the study.

         18. Subject is pregnant or planning to become pregnant during the study period.

        Intraoperative exclusion criteria (by fluoroscopy angiogram):

          1. Total occlusion of the Target lesion that cannot be crossed in the true lumen by
             0.014&quot; GW.

          2. Target lesion length &gt;25 cm.

          3. Reference vessel lumen diameter proximal to target lesion is &lt;150% of the outer
             diameter of the B-Laser™.

          4. Any clinical and/or angiographic complication attributed to the use of another device
             prior to the study procedure.

          5. Flow limiting dissection proximal, distal or in the target lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yossi Muncher, Ph.D., MBA</last_name>
    <role>Study Director</role>
    <affiliation>Eximo Medical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waclaw Kuczmik, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katowicach Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grzegorz Oszkinis, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniwersytetu Medycznego, Im. Karola Marcinkowskiego w Poznaniu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Katowice</city>
        <zip>40635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>61848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <results_first_submitted>July 19, 2018</results_first_submitted>
  <results_first_submitted_qc>October 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2019</results_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>PAD</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Arterial Occlusive Diseases</keyword>
  <keyword>Peripheral Vascular Diseases</keyword>
  <keyword>PVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02556255/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>B-Laser™ Atherectomy Catheter</title>
          <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B-Laser™ Atherectomy Catheter</title>
          <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ABI (Ankle Brachial Index)</title>
          <description>ABI is calculated as the ratio of the ankle blood pressure to the arm blood pressure. The normal value ranges between 0.9 to 1.3. Higher ABI score represents a better outcome</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.57" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 30 Day Freedom From Major Adverse Events</title>
        <description>Need for emergency surgical revascularization of the target limb
Unplanned target limb amputation above the ankle
Clinically driven Target Lesion Revascularization (TLR)
Cardiovascular related deaths</description>
        <time_frame>30 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 30 Day Freedom From Major Adverse Events</title>
          <description>Need for emergency surgical revascularization of the target limb
Unplanned target limb amputation above the ankle
Clinically driven Target Lesion Revascularization (TLR)
Cardiovascular related deaths</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (1)</title>
        <description>(*NOTE: Device- or procedure-related AE refers only to the ATHERECTOMY PROCEDURE (with B-Laser™) and not the entire index procedure.)
Clinically Significant Perforations requiring intervention
Clinically Significant Dissections requiring intervention
Clinically Significant Embolus requiring intervention
Clinically Pseudo-aneurysm requiring intervention</description>
        <time_frame>Perioperative (until discharge), an average of 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (1)</title>
          <description>(*NOTE: Device- or procedure-related AE refers only to the ATHERECTOMY PROCEDURE (with B-Laser™) and not the entire index procedure.)
Clinically Significant Perforations requiring intervention
Clinically Significant Dissections requiring intervention
Clinically Significant Embolus requiring intervention
Clinically Pseudo-aneurysm requiring intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Lesions With Technical Success Rate: the Ability of the B-Laser™ Catheter to Cross the Target Lesion Stenosis Over the Wire.</title>
        <description>The technical success will be evaluated visually by the performing physician during procedure by fluoroscopy. It is evaluated per lesion and not per subject</description>
        <time_frame>Intraoperative (during the index procedure, after B-Laser™ catheter crossing, before adjunctive therapy)</time_frame>
        <population>Generally angiographic outcomes are evaluated per lesions (53) and not per participants (50). Yet, this specific endpoint is analyzed for 52 lesions (instead of 53), since the data for this timepoint in one participant with one lesion was missing for evaluation of this specific endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions With Technical Success Rate: the Ability of the B-Laser™ Catheter to Cross the Target Lesion Stenosis Over the Wire.</title>
          <description>The technical success will be evaluated visually by the performing physician during procedure by fluoroscopy. It is evaluated per lesion and not per subject</description>
          <population>Generally angiographic outcomes are evaluated per lesions (53) and not per participants (50). Yet, this specific endpoint is analyzed for 52 lesions (instead of 53), since the data for this timepoint in one participant with one lesion was missing for evaluation of this specific endpoint.</population>
          <units>lesions</units>
          <param>Count of Units</param>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (2)</title>
        <description>(*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.)
Emboli, defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator
Flow limiting dissection</description>
        <time_frame>Perioperative (until discharge), an average of 6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (2)</title>
          <description>(*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.)
Emboli, defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator
Flow limiting dissection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 30 Day Freedom From Device/Procedure* Related Adverse Events</title>
        <description>(*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.)
Clinically Significant Dissections requiring intervention
Clinically Significant Embolus requiring intervention
Clinically Pseudo-aneurysm requiring intervention</description>
        <time_frame>30 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 30 Day Freedom From Device/Procedure* Related Adverse Events</title>
          <description>(*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.)
Clinically Significant Dissections requiring intervention
Clinically Significant Embolus requiring intervention
Clinically Pseudo-aneurysm requiring intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lesions With Post-intervention Residual Diameter Stenosis of &lt;30% With Adjunctive Therapy Assessed by Fluoroscopic Angiography in Cases Where Adjunctive Therapy is Medically Applicable</title>
        <description>The ability of the B-Laser™ catheter to achieve a post-intervention residual diameter stenosis of &lt;30% with adjunctive therapy assessed by fluoroscopic angiography in cases where adjunctive therapy is medically applicable</description>
        <time_frame>Intraoperative (at the end of the index procedure, after the last adjunctive therapy, e.g. last balloon or last stent)</time_frame>
        <population>This endpoint is analyzed for lesions (53) and not for participants (50)</population>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions With Post-intervention Residual Diameter Stenosis of &lt;30% With Adjunctive Therapy Assessed by Fluoroscopic Angiography in Cases Where Adjunctive Therapy is Medically Applicable</title>
          <description>The ability of the B-Laser™ catheter to achieve a post-intervention residual diameter stenosis of &lt;30% with adjunctive therapy assessed by fluoroscopic angiography in cases where adjunctive therapy is medically applicable</description>
          <population>This endpoint is analyzed for lesions (53) and not for participants (50)</population>
          <units>lesions</units>
          <param>Count of Units</param>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle-Brachial Index (ABI) Post B-Laser™ Device Procedure Compared to Baseline</title>
        <description>Change in Ankle-Brachial Index (ABI) post B-Laser™ device procedure compared to baseline.
ABI is calculated as the ratio of the ankle blood pressure to the arm blood pressure. The normal value ranges between 0.9 to 1.3.
The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher ABI score at the later time point represents an improvement through time and vice versa.</description>
        <time_frame>baseline and 30 days, 6 months and 12 months post procedure</time_frame>
        <population>The number analyzed in one or more rows differs from overall number since it excludes missing data at different time-points</population>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle-Brachial Index (ABI) Post B-Laser™ Device Procedure Compared to Baseline</title>
          <description>Change in Ankle-Brachial Index (ABI) post B-Laser™ device procedure compared to baseline.
ABI is calculated as the ratio of the ankle blood pressure to the arm blood pressure. The normal value ranges between 0.9 to 1.3.
The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher ABI score at the later time point represents an improvement through time and vice versa.</description>
          <population>The number analyzed in one or more rows differs from overall number since it excludes missing data at different time-points</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline</title>
        <description>Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline.
Rutherford Classification has seven stages, from Stage 0 to Stage 6, when the lower value indicate a better outcome: 0= Asymptomatic; 1= Mild claudication; 2= Moderate claudication; 3= Severe claudication; 4= Rest pain; 5= Ischemic ulceration not exceeding ulcer of the digits of the foot; 6= Severe ischemic ulcers or frank gangrene.
The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent decrease while negative results represent increases, so lower Rutherford score at the later time point represents an improvement through time and vice versa.</description>
        <time_frame>baseline and 30 days, 6 months and 12 months post procedure</time_frame>
        <population>The number analyzed in one or more rows differs from overall number since it excludes missing data at different time-points</population>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline</title>
          <description>Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline.
Rutherford Classification has seven stages, from Stage 0 to Stage 6, when the lower value indicate a better outcome: 0= Asymptomatic; 1= Mild claudication; 2= Moderate claudication; 3= Severe claudication; 4= Rest pain; 5= Ischemic ulceration not exceeding ulcer of the digits of the foot; 6= Severe ischemic ulcers or frank gangrene.
The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent decrease while negative results represent increases, so lower Rutherford score at the later time point represents an improvement through time and vice versa.</description>
          <population>The number analyzed in one or more rows differs from overall number since it excludes missing data at different time-points</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Rutherford class 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Rutherford class 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Rutherford class 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Rutherford class 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford class 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline</title>
        <description>Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline. WIQ score ranges from 0-100 with higher score indicating a better walking outcomes.
The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher WIQ score at the later time point represents an improvement through time and vice versa.</description>
        <time_frame>baseline and 30 days, 6 months and 12 months post procedure</time_frame>
        <population>The number analyzed in one or more rows differs from overall number since it excludes missing data at different time-points.
Answers to all questions in the Walking Impairment Questionnaire (WIQ) must be provided to obtain a valid result, incomplete questionnaires were not considered.</population>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline</title>
          <description>Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline. WIQ score ranges from 0-100 with higher score indicating a better walking outcomes.
The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher WIQ score at the later time point represents an improvement through time and vice versa.</description>
          <population>The number analyzed in one or more rows differs from overall number since it excludes missing data at different time-points.
Answers to all questions in the Walking Impairment Questionnaire (WIQ) must be provided to obtain a valid result, incomplete questionnaires were not considered.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.16" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.72" spread="19.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.84" spread="22.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.30" spread="18.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Lesions With Post-intervention Residual Diameter Stenosis of ≤30% With Adjunctive Therapy Assessed by Fluoroscopic Angiography in Cases Where Adjunctive Therapy is Medically Applicable</title>
        <description>EX-PAD-01 study secondary efficacy endpoint of the post adjunctive therapy residual diameter stenosis, was set per protocol with a threshold at &lt;30%, however, in many other atherectomy studies, this threshold is set at ≤30%, Therefore results with this threshold are presented as well</description>
        <time_frame>Intraoperative (at the end of the index procedure, after the last adjunctive therapy, e.g. last balloon or last stent)</time_frame>
        <population>This endpoint is analyzed for lesions (53) and not for participants (50)</population>
        <group_list>
          <group group_id="O1">
            <title>B-Laser™ Atherectomy Catheter</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions With Post-intervention Residual Diameter Stenosis of ≤30% With Adjunctive Therapy Assessed by Fluoroscopic Angiography in Cases Where Adjunctive Therapy is Medically Applicable</title>
          <description>EX-PAD-01 study secondary efficacy endpoint of the post adjunctive therapy residual diameter stenosis, was set per protocol with a threshold at &lt;30%, however, in many other atherectomy studies, this threshold is set at ≤30%, Therefore results with this threshold are presented as well</description>
          <population>This endpoint is analyzed for lesions (53) and not for participants (50)</population>
          <units>lesions</units>
          <param>Count of Units</param>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days, 6 months and 12 months post procedure with B-Laser™ device</time_frame>
      <desc>If multiple terms (events) were coded within 1 reported event in eCRF, they were connected with ‘@’ sign. E.g. LLT terms ‘Upper gastrointestinal hemorrhage@Esophagitis@Gastroesophageal reflux disease’ denotes the event description reported in eCRF: ‘Upper gastrointestinal hemorrhage (mild) occurred on 15.03, resulted in hospitalization between 28-31.03. During hospital stay chest CT was done and endoscopic evaluation of upper GI tract, that revealed esophagitis, gastroesophageal reflux disease’.</desc>
      <group_list>
        <group group_id="E1">
          <title>B-Laser™ Atherectomy Catheter</title>
          <description>Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD) that the atherectomy part of the PTA includes an experimental atherectomy catheter, B-Laser™.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>LLT and SOC MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <description>329 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <description>144 &amp; 356 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Chronic ischemic heart disease, unspecified</sub_title>
                <description>82 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Non STEMI@Atrioventricular block@Cardiogenic shock@Acute renal failure</sub_title>
                <description>322 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Non STEMI@ Bradycardia</sub_title>
                <description>319 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Angina pectoris unstable</sub_title>
                <description>308 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>319 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <description>8 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Large intestine angiodysplasia</sub_title>
                <description>126 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage@ Esophagitis@ Gastroesophageal reflux disease</sub_title>
                <description>92 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access site hematoma</sub_title>
                <description>0 days post procedure. Not related to the Investigational Device. Causal relationship to the index procedure.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <description>232 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial femoral arterial stenosis &amp; Claudication@Leg ischemia@Disease progression</sub_title>
                <description>8 &amp; 197 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Leg ischemia@Superficial femoral arterial stenosis@Claudication</sub_title>
                <description>384 days post procedure. Not related to the Investigational Device. Possibly related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Leg ischemia@ Popliteal arterial restenosis</sub_title>
                <description>245 days post procedure. Might be related to both device or Index procedure and judged to be more due to Index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>LLT and SOC MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema lower limb</sub_title>
                <description>4 &amp; 28 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <description>180 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <description>0 days post procedure. Not related to the Investigational Device. Definitely related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>287 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal bleeding</sub_title>
                <description>20 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular dissection</sub_title>
                <description>0 days post procedure. Not related to the Investigational Device. Definitely related to the index procedure. Minor dissection.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Arterial occlusion</sub_title>
                <description>163 days post procedure. Not related to the Investigational Device. Related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Leg ischemia@Superficial femoral arterial stenosis</sub_title>
                <description>195 &amp; 207 &amp; 221 &amp; 324 days post procedures. Not related to the Investigational Device. Probably not related to the index procedure.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Leg ischemia</sub_title>
                <description>188 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <description>31 days post procedure. Not related to the Investigational Device. Not related to the index procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Oshrat Cohen</name_or_title>
      <organization>Eximo Medical</organization>
      <phone>97286307639</phone>
      <email>oshratc@eximomedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

